Ferrante Karen Jean 4
Research Summary
AI-generated summary
MacroGenics (MGNX) Director Karen Ferrante Exercises Options, Receives RSUs
What Happened
- Karen Jean Ferrante, a MacroGenics (MGNX) director, exercised/converted 3,750 derivative shares on May 18, 2026. That same exercise shows a disposition of 3,750 shares at $0.00 (common when shares are withheld to cover taxes). On May 19, 2026 she was recorded as receiving two awards totaling 25,750 restricted stock units (3,750 RSUs and 22,000 RSUs) at $0.00.
- No cash value was reported for the awards in the filing; the $0.00 amounts reflect equity awards/settlements rather than open-market purchases or sales. These actions are typical equity compensation events rather than a market buy or sell.
Key Details
- Transaction dates and prices: 5/18/2026 — exercise/conversion of 3,750 shares (Acquired); 5/18/2026 — disposition of 3,750 shares at $0.00 (likely tax withholding); 5/19/2026 — grants/awards of 3,750 RSUs and 22,000 RSUs at $0.00.
- Shares owned after transaction: Not specified in the filing.
- Notable footnotes: F1 — each RSU equals a contingent right to one share; F2 — RSUs vested on May 18, 2026 (one day before the May 19 annual meeting); F3 — RSUs vest either one year after grant or the day before the next annual meeting if earlier; F4 — the option vests monthly in cumulative 1/12 increments starting one month after grant.
- Timeliness: Filing dated May 20, 2026 for transactions on May 18–19, 2026 — appears timely (no late filing indicated).
Context
- These entries reflect compensation-related activity (option exercise and RSU awards/vests), not an open-market purchase or sale that signals a direct investment decision. The $0.00 disposition line is consistent with shares withheld to satisfy tax or other withholding obligations upon exercise/vesting.